Giovannoni Gavin, Boyko Alexey, Correale Jorge, Edan Gilles, Freedman Mark S, Montalban Xavier, Rammohan Kottil, Stefoski Dusan, Yamout Bassem, Leist Thomas, Aydemir Aida, Borsi Laszlo, di Cantogno Elisabetta Verdun
Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Pirogov Russian National Research Medical University, Department of Neurology, Neurosurgery & Medical Genetics, Federal Center of Brain Research & Neurotechnologies, Moscow, Russia.
Neurodegener Dis Manag. 2023 Oct;13(5):261-268. doi: 10.2217/nmt-2023-0018. Epub 2023 Aug 3.
WHAT IS THIS SUMMARY ABOUT?: Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies.
WHAT WERE THE RESULTS?: Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS.
WHAT DO THE RESULTS MEAN?: The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.
本摘要内容是什么？：先前的研究表明，接受克拉屈滨片治疗的多发性硬化症（MS）患者复发次数较少（出现新症状或现有症状持续恶化24小时或更长时间），且残疾进展延缓（疾病恶化速度减慢）。CLASSIC-MS研究观察了参与最初的CLARITY和CLARITY扩展临床研究的MS患者使用克拉屈滨片治疗的长期疗效。
结果如何？：结果显示，接受克拉屈滨片治疗的患者在更长时间内保持了行动能力（自由移动的能力），并且在治疗结束后的很长时间内都经历了其他积极影响，包括不太可能因MS需要进一步治疗。
这些结果意味着什么？：CLASSIC-MS研究获得的结果表明，即使患者停止服用克拉屈滨片，服用该药的益处仍然存在。
